Jpmorgan Chase & CO Alvotech Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Alvotech stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,368 shares of ALVO stock, worth $56,871. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,368
Previous 301
1351.16%
Holding current value
$56,871
Previous $3,000
1666.67%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ALVO
# of Institutions
34Shares Held
15MCall Options Held
100KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA3.16MShares$41.1 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$35.2 Million47.01% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca2.53MShares$33 Million0.61% of portfolio
-
Littlejohn & CO LLC1.32MShares$17.2 Million6.78% of portfolio
-
Legal & General Group PLC London, X01MShares$13 Million0.0% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $3.24B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...